Cryoport leads fragmented cell and gene therapy logistics market

The cell and gene therapy supply chain and logistics market remains fragmented, with specialized cold chain providers competing on temperature control, shipment visibility, and regulatory compliance. Cryoport led global sales in 2024, while new partnerships and cryogenic packaging tools are shaping how advanced therapies move from manufacturers to patients.

Why it matters: - Cell and gene therapies depend on tightly controlled logistics to preserve product integrity from manufacturing to patient delivery. - The market is expanding as more advanced therapies move into clinical and commercial use. - Competitive advantages now center on cold chain reliability, chain-of-custody tracking, and scalable distribution networks. - The market also matters because patient-specific therapies leave little room for transit delays or temperature excursions.

What happened: - The Business Research Company said Cryoport Inc. led global sales in 2024 with a 2% market share. - The company identified the cell and gene therapy supply chain/logistics market as fairly fragmented, with the top 10 players accounting for 14% of total market revenue in 2024. - The report listed Cryoport Inc., World Courier, Thermo Fisher Scientific Inc., Lonza Group AG, United Parcel Service, Catalent Inc., BioLife Solutions Inc., QuickSTAT, Biocair Inc., and PCI Pharma Services as the leading companies. - The report also named dozens of other active players, raw material suppliers, wholesalers, distributors, and end users across the market.

The details: - Cryoport’s biopharma logistics division provides cryogenic transportation, temperature-controlled packaging, biologic material tracking, and integrated logistics services for clinical and commercial cell and gene therapy applications. - Major raw material suppliers include Avantor Sciences, Sartorius AG, Merck KGaA, Danaher Corporation, Corning Incorporated, FUJIFILM Irvine Scientific, Repligen Corporation, Saint-Gobain Life Sciences, Cytiva Life Science Ltd., Lonza Group AG, Nipro Corporation, Eppendorf SE, Miltenyi Biotec, Bio-Techne Corporation, Asahi Kasei Corporation, Terumo Corporation, 3M Company, Pall Corporation, Thermo Fisher Scientific Inc., and Charles River Laboratories International. - Major wholesalers and distributors include World Courier, United Parcel Service, DHL Group, FedEx Corporation, Cryoport Inc., Biocair Inc., QuickSTAT, PCI Pharma Services, Yourway Biopharma Services Company, Polar Express Transportation, Kuehne+Nagel, DB Schenker, GEODIS, XPO Logistics, Agility Logistics, Arvato Group, Movianto, Marken, SF Express, and Lineage Logistics. - Major end users include Novartis AG, Gilead Sciences Inc., Bristol Myers Squibb, Pfizer Inc., Johnson & Johnson, Roche Holding AG, bluebird bio, CRISPR Therapeutics, Beam Therapeutics, Editas Medicine, Sana Biotechnology, Adaptimmune Therapeutics, Autolus Therapeutics, 2seventy bio, Allogene Therapeutics, Fate Therapeutics, Orchard Therapeutics, uniQure N.V., Legend Biotech, and Caribou Biosciences. - The report highlighted four strategy areas: advanced cryogenic packaging, real-time shipment monitoring, strategic collaborations, and automation and digital chain-of-custody platforms.

Between the lines: - A 14% share for the top 10 players points to a market that is still open, even as barriers to entry stay high. - Regulatory requirements and biologics handling standards continue to favor specialists with validated cold chain infrastructure. - Logistics firms are moving closer to manufacturing by offering integrated services instead of transport alone. - The partnership model is becoming more important as therapies require end-to-end handling across borders and between facilities. - In June 2024, Cryoport partnered with Minaris Regenerative Medicine to provide integrated logistics and manufacturing services for regenerative medicine products and advanced cell and gene therapies.

What's next: - The report expects service innovation, strategic partnerships, and global network expansion to strengthen leading companies as demand for personalized medicine grows. - Wider adoption of real-time monitoring and digital custody tools is likely to increase shipment visibility and compliance. - More integrated logistics-manufacturing partnerships are likely as companies try to improve delivery efficiency for patient-specific treatments. - The Business Research Company is offering a free sample of the report and a detailed market report.

The bottom line: - Cryoport is the current leader, but the market remains fragmented and competitive, with growth tied to cold chain precision, compliance, and partnerships that can support advanced therapies at scale.